My laboratory studies a protein modification, arginine methylation, that can change and regulate the function of proteins. We have discovered that the molecules responsible for this modification, the PRMTs, are found at abnormally high levels in breast cancer. Hence, we wish to test if defects in the pathways that PRMTs normally regulate are contributing to breast cancer. Using a combination of highly innovative approaches, we will (i) test for the predictive value of new biomarkers, which could facilitate early diagnosis and help predict the outcome of breast cancers, (ii) investigate the role of PRMTs in breast cancer progression and (iii) identify in an unbiased fashion the proteins that are aberrantly arginine methylated in breast cancer. This work could uncover novel pathways involved in breast cancer, opening up new fields of investigation. Molecules identified in this study also represent potential new targets for the development of original therapeutic strategies.